MFN2 and neurodegenerative disease: Previous studies have shown that Mfn2 agonists could reverse mitochondrial defects in preclinical models of neurodegenerative disease of Charcot Marie Tooth disease type 2A (CMT2A) by mechanistically ameliorating mitochondrial trafficking33.